Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Research Abstract Details 

Research Abstract Table of Contents

Jump to the:

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Abstract Text:

Autophagy is a major clearance route for intracellular aggregate-prone proteins causing diseases such as Huntington's disease. Autophagy induction with the mTOR inhibitor rapamycin accelerates clearance of these toxic substrates. As rapamycin has nontrivial side effects, we screened FDA-approved drugs to identify new autophagy-inducing pathways. We found that L-type Ca2+ channel antagonists, the K+ATP channel opener minoxidil, and the G(i) signaling activator clonidine induce autophagy. These drugs revealed a cyclical mTOR-independent pathway regulating autophagy, in which cAMP regulates IP3 levels, influencing calpain activity, which completes the cycle by cleaving and activating G(s)alpha, which regulates cAMP levels. This pathway has numerous potential points where autophagy can be induced, and we provide proof of principle for therapeutic relevance in Huntington's disease using mammalian cell, fly and zebrafish models. Our data also suggest that insults that elevate intracytosolic Ca2+ (like excitotoxicity) inhibit autophagy, thus retarding clearance of aggregate-prone proteins.

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Publishing Authors By Initials

For similar abstracts research abstracts see: abstracts research

PUBMED ID PMID:

MEDLINE DATE:

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Journal Published:

PUBLICATION TYPE: Research Support, Non-U.S. Gov

Journal: Nature chemical biology

VOLUME: 4

Page Numbers: 295-305

Journal Abbreviation: Nat. Chem. Biol.

ISSN: 1552-4469

DAY: 22

MONTH: May

YEAR: 2008

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Information

Number of References:

LANGUAGE: eng

NlmUniqueID: 101231976

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Keywords Mesh Terms:

KEYWORDS:

MESH TERMS:

Chemical & Substance for Abstract: Novel targets for Huntington's disease in an mTOR-independent autophagy pathway. Information

Substance Name:

Registry Number:

Grant and Affiliation Information for Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.

AFFILIATION: Department of Medical Genetics, University of Cambridge, Cambridge Institute for Medical Research, Addenbrooke's Hospital, Hills Road, Cambridge CB2 0XY, UK.

Country: United States

AGENCY: United Kingdom Wellcome T

GRANT:

ACRONYM:

MEDLINETA: Nat Chem Biol

REFSOURCE:

DATABASENAME:

ACCESSION NUMBER:

Number Hits: 0

Novel targets for Huntington's disease in an mTOR-independent autophagy pathway Related Publications

• A rational mechanism for combination treatment of Huntington's disease using lithium and rapamycin.
• Apo E and Apo CI loci are associated with dementia in younger but not older late-onset cases.
• Candidate gene association studies of genes involved in neuronal cholinergic transmission in Alzheimer's disease suggests choline acetyltransferase as a candidate deserving further study.
• Clearance of mutant aggregate-prone proteins by autophagy.
• Does bafilomycin A(1) block the fusion of autophagosomes with lysosomes?
• Huntington's disease: degradation of mutant huntingtin by autophagy.
• Huntington's disease: from pathology and genetics to potential therapies.
• Loss of PINK1 function affects development and results in neurodegeneration in zebrafish.
• Novel targets for Huntington's disease in an mTOR-independent autophagy pathway.
• Rab5 modulates aggregation and toxicity of mutant huntingtin through macroautophagy in cell and fly models of Huntington disease.
• Small molecule enhancers of autophagy for neurodegenerative diseases.
• Small molecule enhancers of rapamycin-induced TOR inhibition promote autophagy, reduce toxicity in Huntington's disease models and enhance killing of mycobacteria by macrophages.
• Spinocerebellar ataxias caused by polyglutamine expansions: A review of therapeutic strategies.
• The itinerary of autophagosomes: from peripheral formation to kiss-and-run fusion with lysosomes.
• The ubiquitin proteasome system in Huntington's disease and the spinocerebellar ataxias.
• Wild-type PABPN1 is anti-apoptotic and reduces toxicity of the oculopharyngeal muscular dystrophy mutation.
• p21-activated kinase 1 promotes soluble mutant huntingtin self-interaction and enhances toxicity.